This is a HER2 news story, published by ScienceDaily, that relates primarily to Trastuzumab news.
For more HER2 news, you can click here:
more HER2 newsFor more Trastuzumab news, you can click here:
more Trastuzumab newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from ScienceDaily, you can click here:
more news from ScienceDailyOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
breast cancer cells. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest drug conjugate news, Antibody news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
positive advanced breast cancerScienceDaily
•79% Informative
An antibody-drug conjugate found effective against brain metastases in patients with HER2-positive breast cancer.
Trastuzumab deruxtecan (T-DXd) delivers chemotherapy directly to tumors.
The findings reinforce earlier findings of the benefits of the drug in these patients.
Trastuzumab deruxtecan in HER2 -positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.
The study is published in Nature Medicine , 2024 ; DOI: 10.1038 /s41591/024-024-032617.
VR Score
89
Informative language
95
Neutral language
68
Article tone
formal
Language
English
Language complexity
65
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links